+441518081136Does a single dose of adenosine in epidural space reduce cancer-related neuropathic pain? A randomized clinical trial
16th International Conference on Oncology Nursing and Cancer Care
April 15-16, 2019 | Frankfurt, Germany
Ehsan Shahverdi
University Medicine Greifswald, Germany
Posters & Accepted Abstracts : J Med Oncl Ther
Abstract:
Background: Systemic and intrathecal adenosine
reduce chronic neuropathic and nociceptive
pain; however, the effect of adenosine epidural
injection in the treatment of neuropathic cancerrelated
pains remains unclear.
Objectives: The objective of this study was to
evaluate the efficacy of a single epidural administration
of adenosine in alleviating chronic neuropathic pain
in patients with primitive neuroectodermal tumors.
Methods: In this single-blind randomized clinical
trial with the unique ID of IRCT2017031428878N1,
88 patients with chronic neuropathic pain were
divided into two equivalent groups. Two groups were
treated with a single dose epidural administration of
ropivacaine, 0.75 mL/kg from 0.2% solution (both
groups), plus adenosine, 50 mcgr/kg (adenosine
group), or normal saline (control group). Patients
were evaluated on the days 1, 2, 3, 5, 7, 10, and 14
after injection.
Results: Both groups showed a reduction in pain
severity according to verbal rating scale (VRS) (3
± 0.09-1 ± 0.05 in adenosine, 4 ± 0.08-1 ± 0.00 in
the control group) and visual analogue scale (VAS)
(7 ± 0.25-1 ±0.12 in adenosine, 8 ±0.22-1 ± 0.06
in the controlgroup); however, this reductionwas
significantlyhigher in the controlgroup(P< 0.0005).
The intensityof neuropathicpain decreased in both
groups according to Douleur Neuropathique 4
questions (DN4) scores(from 5 ± 0.23-1 ± 0.04 in
adenosine group, and from 5.5 ± 0.24-1 ± 0.00 in
the control group) without a significant difference
between the groups (P=0.19). Adenosine group had
less nausea and vomiting (P<0.0005).There was no
significant difference in patient satisfaction levels
between adenosine and control groups (P=0.09).
Conclusions: Administration of bolus epidural
adenosine is not effective in reducing neuropathic pain
in patients with primitive neuroectodermal tumors.
Biography:
Ehsan Shahverdi is a MD medical graduate (2016), who commenced his interest in Blood transfusion, cancer treatment and research in 2014. He completed a MD postgraduate qualifications before taking up positions in transfusion in Iranian Blood Transfusion Organization (IBTO) and then in cancer treatment and research in MAHAK Pediatric Cancer Treatment and Research Center. He has been a Council member of the Blood and Cancer Research Center of the MAHAK Pediatric Cancer Treatment and Research Center. He is Chairman of the department of Young Doctors and Researchers of the IPHOS. He has written over 70 scientific papers and is in demand as a speaker to a number of international congress. He has a particular interest in the transfusion services of developing countries and has travelled to many of them to lecture and assist in practical workshops. Over the years, he has been awarded life memberships of various organizations and has won several prestigious awards from medical societies. He is now very active in various community support organizations.
E-mail: ehsan.shahverdi@uni-greifswald.de
PDF HTML